Source: PR Newswire

Press Release: Affera : Affera Announces First Patient Treated in SPHERE Per-AF IDE Trial

NEWTON, Mass., Dec. 20, 2021 /PRNewswire/ -- Affera Inc., a private medical device company focused on innovative cardiac arrhythmia treatment solutions, announced today that the first patient was treated in the recently approved SPHERE PerAF Trial, a U.S. Food and Drug Administration...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Doron Harlev's photo - Founder & CEO of Affera

Founder & CEO

Doron Harlev

CEO Approval Rating

90/100

Read more